Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688142 · ClinicalTrials.gov registry record
Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 24
- Enrollment target
NCT00688142: Completed study, sponsored by Henry Ford Health System.
NCT00688142 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00688142 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The investigators hypothesize that in patients with shift work sleep disorder, armodafinil will specifically increase brain activity in the frontal cortex parallel with improvements in deficits of fundamental mechanisms of attention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-03 |
What the finished NCT00688142 record still lists
NCT00688142 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00688142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00688142 about?
NCT00688142 is a clinical study titled "Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder". The investigators hypothesize that in patients with shift work sleep disorder, armodafinil will specifically increase brain activity in the frontal cortex parallel with improvements in deficits of fundamental mechanisms of attention.
What is the current status of trial NCT00688142?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2008-02. Estimated completion is 2010-03.
Who is sponsoring clinical trial NCT00688142?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia